Real-World study tracks darolutamide use in advanced prostate cancer
NCT ID NCT07406282
First seen Feb 26, 2026 · Last updated May 14, 2026 · Updated 8 times
Summary
This study observes how men with metastatic hormone-sensitive prostate cancer (mHSPC) are treated with darolutamide in everyday urology clinics across the US. Researchers will review medical records of about 1,400 patients to understand who gets which treatment (darolutamide with or without chemotherapy) and how they fare. The goal is to fill knowledge gaps and help guide future treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company
RECRUITINGCleveland, Ohio, 44114-2619, United States
Conditions
Explore the condition pages connected to this study.